Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Gefitinib Stories

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

2014-03-28 23:04:53

Markets Research Reports.biz added deep and professional market research reports on "NSCLC Therapeutics In Asia-Pacific Markets To 2019 - Personalized Therapies Focus On Untapped Segment Of Squamous Cell Carcinoma To Expand Treatment Pool" Market Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis-details/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool....

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...

2014-03-15 08:21:28

DALLAS, March 15, 2014 /PRNewswire/ -- ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store. According to Epilepsy Therapeutics in Asia Pacific Markets to...

2013-11-04 23:19:01

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch...

2013-11-04 23:04:31

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of...

2013-10-31 12:25:01

Interviewed Payers Say Biomarker-Driven Prescribing is an NSCLC Market Access Lever, But Optimal Pivotal Trial Design is Also Key, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain, and the United Kingdom) currently prescribe the...

2013-10-21 10:09:54

The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung...

2013-10-16 23:23:56

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022. London (PRWEB) October 16, 2013 PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch...

2013-10-16 04:21:50

SAN DIEGO, Calif., Oct. 16, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) "We are pleased to launch a...